store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 53.00 | |
10 mg | In stock | $ 83.00 | |
25 mg | In stock | $ 135.00 | |
50 mg | In stock | $ 197.00 | |
100 mg | In stock | $ 289.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 59.00 |
Description | D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). |
Targets&IC50 | PC-PLC:6.4 μM (Ki) |
In vitro | D609 (100 μM; 2 hours) significantly inhibits the proliferation of various cell lines[2].At concentrations of 50, 100, and 200 μM (2 hours), D609 activates caspase-3 at 200 μM, while at 50 and 100 μM, no detectable cleavage is observed[2].D609 (100 μM; 2 hours) markedly inhibits BrdU incorporation in BV-2 microglial cells, leading to G1 phase cell accumulation and a decrease in the number of cells in the S phase[2].D609 (100 μM; 2 hours, followed by 2 or 22 hours of cultivation without D609) increases ceramide levels, upregulates p21 expression, and results in decreased phosphorylation of Rb[4]. |
In vivo | D609 (2.5 and 10 mg/kg/day; intraperitoneal injection; continuous for 6 weeks) inhibits the progression of pre-existing atherosclerotic lesions in apoE-/- mice and transforms the lesion composition into a more stable phenotype[3].Pre-treatment with D609 (50 mg/kg; intraperitoneal injection; single dose) 30 minutes before intratracheal administration of LPS (3 mg/kg) prevents lipopolysaccharide-induced pulmonary arterial hypertension in adult male Wistar rats[2]. |
Molecular Weight | 266.46 |
Formula | C11H15KOS2 |
CAS No. | 83373-60-8 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 1 mg/mL (3.75 mM), Sonication is recommended.
DMSO: 80 mg/mL (300.23 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
D609 83373-60-8 Apoptosis oxidation-reduction Antioxidant D 609 D-609 inhibitor inhibit